These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24119427)

  • 1. Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA.
    Aballéa S; Guelfucci F; Wagner J; Khemiri A; Dietz JP; Sobel J; Toumi M
    Health Qual Life Outcomes; 2013 Oct; 11():169. PubMed ID: 24119427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey.
    Yoo HK; Porteous A; Ng A; Haria K; Griffiths A; Lloyd A; Yang X; Kazeem G; Barut V
    BMC Neurol; 2023 Nov; 23(1):419. PubMed ID: 37996843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent Vulvovaginal Candidiasis: Assessing the relationship between feminine/vaginal washes and other factors among Ghanaian women.
    Otoo-Annan E; Senoo-Dogbey VE
    BMC Public Health; 2024 Jan; 24(1):100. PubMed ID: 38183091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-sectional survey of work and income loss consideration among patients with herpes zoster when completing a quality of life questionnaire.
    Johnson KD; Brenneman SK; Newransky C; Sheffler-Collins S; Becker LK; Belland A; Acosta CJ
    BMC Health Serv Res; 2018 Aug; 18(1):662. PubMed ID: 30144806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis.
    Sobel JD; Donders G; Degenhardt T; Person K; Curelop S; Ghannoum M; Brand SR
    NEJM Evid; 2022 Aug; 1(8):EVIDoa2100055. PubMed ID: 38319878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosocial impact of recurrent urogenital infections: a review.
    Thomas-White K; Navarro P; Wever F; King L; Dillard LR; Krapf J
    Womens Health (Lond); 2023; 19():17455057231216537. PubMed ID: 38099456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hungarian population norms for the 15D generic preference-accompanied health status measure.
    Nikl A; Janssen MF; Brodszky V; Rencz F
    Qual Life Res; 2024 Jan; 33(1):87-99. PubMed ID: 37707653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From simple to even simpler, but not too simple: a head-to-head comparison of the Better-Worse and Drop-Down methods for measuring patient health status.
    Zhang X; Krabbe PFM
    BMC Med Res Methodol; 2023 Dec; 23(1):299. PubMed ID: 38104119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent vulvovaginal candidiasis.
    Sobel JD
    Am J Obstet Gynecol; 2016 Jan; 214(1):15-21. PubMed ID: 26164695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of persistent vaginitis.
    Nyirjesy P
    Obstet Gynecol; 2014 Dec; 124(6):1135-1146. PubMed ID: 25415165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis.
    Zhu YX; Li T; Fan SR; Liu XP; Liang YH; Liu P
    Health Qual Life Outcomes; 2016 Apr; 14():65. PubMed ID: 27129474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors.
    Gonçalves B; Ferreira C; Alves CT; Henriques M; Azeredo J; Silva S
    Crit Rev Microbiol; 2016 Nov; 42(6):905-27. PubMed ID: 26690853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes.
    Yano J; Sobel JD; Nyirjesy P; Sobel R; Williams VL; Yu Q; Noverr MC; Fidel PL
    BMC Womens Health; 2019 Mar; 19(1):48. PubMed ID: 30925872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of recurrent vulvovaginal candidiasis on quality of life issues.
    Fukazawa EI; Witkin SS; Robial R; Vinagre JG; Baracat EC; Linhares IM
    Arch Gynecol Obstet; 2019 Sep; 300(3):647-650. PubMed ID: 31270690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent vulvovaginal candidiasis.
    Blostein F; Levin-Sparenberg E; Wagner J; Foxman B
    Ann Epidemiol; 2017 Sep; 27(9):575-582.e3. PubMed ID: 28927765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species.
    Sobel JD; Sobel R
    Expert Opin Pharmacother; 2018 Jun; 19(9):971-977. PubMed ID: 29932786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans.
    Collins LM; Moore R; Sobel JD
    J Low Genit Tract Dis; 2020 Jan; 24(1):48-52. PubMed ID: 31860575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy.
    Crouss T; Sobel JD; Smith K; Nyirjesy P
    J Low Genit Tract Dis; 2018 Oct; 22(4):382-386. PubMed ID: 29975334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global burden of recurrent vulvovaginal candidiasis: a systematic review.
    Denning DW; Kneale M; Sobel JD; Rautemaa-Richardson R
    Lancet Infect Dis; 2018 Nov; 18(11):e339-e347. PubMed ID: 30078662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis.
    Peebles K; Velloza J; Balkus JE; McClelland RS; Barnabas RV
    Sex Transm Dis; 2019 May; 46(5):304-311. PubMed ID: 30624309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.